Drug Trial Radar · NCT05421858
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Dec 11, 2024
Primary completion
Jan 30, 2028
Study completion Jan 30, 2028
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- Jun 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosmanogepix tablets. One-third of all patients will receive a standard of care regimen of caspofungin Intravenous (IV) infusion followed by optional fluconazole capsules. Fosmanogepix or caspofungin will first be given as an Intravenous (IV) infusion directly into a vein in the arm each day at the study clinic. Fosmanogepix tablets or fluconazole capsules will be taken orally by mouth daily either at the study clinic, or at home if patients are well enough to be discharged from the hospital. The treatment effect in patients receiving fosmanogepix to those receiving caspofungin/ fluconazole will be compared. The primary aim is to show that fosmanogepix is not inferior (not worse) to caspofungin/ fluconazole with a noninferiority margin of 15%. The duration of study treatment and number of study visits will vary depending on how long the patient will be treated for the infection. Treatment will continue for a maximum of 6 weeks depending on when the infection is cleared and whether other symptoms related to the infection have improved. There will also be a follow-up visit 6 weeks after the study treatment was stopped.
Conditions
- Candidemia
- Candidiasis, Invasive
Interventions
FosmanogepixDrug
IV infusion
FosmanogepixDrug
Oral tablet
CaspofunginDrug
IV infusion
FluconazoleDrug
Fluconazole oral capsule
PlaceboDrug
Matching placebo for caspofungin (IV infusion)
PlaceboDrug
Matching placebo for fluconazole (oral capsule)
PlaceboDrug
Matching placebo for fosmanogepix (IV infusion)
PlaceboDrug
Matching placebo for fosmanogepix (oral tablet)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients alive at Day 30Time frame: Day 30
- Proportion of patients with an overall response of treatment success at end of study treatment (EOST)Time frame: EOST (up to Day 42)
Locations
146 sites in 20 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham School of Medicine, Department of Medicine
Birmingham, Alabama · Recruiting
City of Hope
Duarte, California · Recruiting
David Geffen School of Medicine at UCLA
Los Angeles, California · Recruiting
UC Davis Medical Center
Sacramento, California · Recruiting
Emory University Hospital - Clifton Road
Atlanta, Georgia · Recruiting
Augusta University Medical Center
Augusta, Georgia · Recruiting
Indiana University Methodist Hospital
Indianapolis, Indiana · Recruiting
University of Kentucky College of Medicine
Lexington, Kentucky · Withdrawn
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
University of Michigan Health System (UMHS) - A. Alfred Taubman Health Care Center
Ann Arbor, Michigan · Recruiting
DMC Harper University Hospital
Detroit, Michigan · Recruiting
Henry Ford Hospital, Department of Medicine, Division of Infectious Diseases
Detroit, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Washington University School of Medicine, Infectious Diseases Clinical Research Unit
St Louis, Missouri · Recruiting
Weill Cornell Medical College - NewYork-Presbyterian Hospital
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania · Recruiting
UPMC Presbyterian
Pittsburgh, Pennsylvania · Recruiting
Houston Methodist Hospital - Texas Medical Center
Houston, Texas · Recruiting
The University of Texas Health Science Center at Houston
Houston, Texas · Recruiting
U.T. MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Texas Health Science Center at San Antonio
San Antonio, Texas · Recruiting
Carilion Clinic
Roanoke, Virginia · Recruiting
Central Hospital de San Isidro Melchor Posse
Buenos Aires, Argentina · Recruiting
Buenos Aires Italian Hospital, Department of Infectious Diseases
Buenos Aires, Argentina · Recruiting
Cordoba Private University Hospital, Department of Infectious Diseases
Córdoba, Argentina · Recruiting
Italian Hospital of La Plata, Department of Infectious Diseases
La Plata, Argentina · Recruiting
Central Hospital Mendoza
Mendoza, Argentina · Terminated
British Sanatorium SA
Rosario, Argentina · Recruiting
Monash Medical Center Clayton
Clayton, Australia · Recruiting
Westmead Hospital
Sydney, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Peter MacCallum Cancer Center, State
Melbourne, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Royal Melbourne Hospital
Parkville, Victoria, Australia · Recruiting
University Hospital Graz, Department of Internal Medicine
Graz, Austria · Recruiting
Kepler University Hospital GmbH, Department of Pulmonology, Clinical Department of Infectious Diseases
Linz, Austria · Recruiting
Medical University Vienna
Vienna, Austria · Recruiting
Hospital Favoriten, Department of Internal Medicine IV - Infectious Diseases and Tropical Medicine
Vienna, Austria · Recruiting
General Hospital Saint-Jan
Bruges, Belgium · Recruiting
Showing 40 of 146 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.